Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administered as an oral tablet (0.2 mg dose level only), or oral suspension (all dose levels)”In the company’s words, NCT05588323 on ClinicalTrials.gov
- Tested for
- Opioid-Induced Constipation (OIC)
- Main trialPhase 1/2
- “The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of naldemedine and nor-naldemedine after a single oral dose of naldemedine in pediatric participants who are receiving or about to receive opioids.”In the company’s words, NCT05588323 on ClinicalTrials.gov
Coming up1
- 15 Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 15 Jun 2028 | Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids | |
| Phase 2Ended | not given | The effect of naldemedine on opioid-induced bowel dysfunction |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026